{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:35:11Z","timestamp":1762144511056},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.semnephrol.2006.05.008","type":"journal-article","created":{"date-parts":[[2006,11,28]],"date-time":"2006-11-28T00:01:06Z","timestamp":1164672066000},"page":"313-318","source":"Crossref","is-referenced-by-count":35,"title":["Recent Advances in Erythropoietic Agents in Renal Anemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Iain C.","family":"Macdougall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2006.05.008_bib1","first-page":"449","article-title":"Erythropoietin levels in uremic nephric and anephric patients","volume":"93","author":"Caro","year":"1979","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib2","first-page":"283","article-title":"The rate and control of baseline red cell production in hematologically stable patients with uremia","volume":"126","author":"Erslev","year":"1995","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib3","first-page":"777","article-title":"Erythropoietin excretion in man following androgens","volume":"70","author":"Alexanian","year":"1967","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib4","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1016\/S0021-9258(19)63387-9","article-title":"Purification of human erythropoietin","volume":"252","author":"Miyake","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib5","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","article-title":"Cloning and expression of the human erythropoietin gene","volume":"82","author":"Lin","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2006.05.008_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/bjoc.2001.1746","article-title":"Development and characterization of novel erythropoiesis stimulating protein (NESP)","volume":"84","author":"Egrie","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib7","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients","volume":"10","author":"Macdougall","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib8","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1046\/j.1523-1755.2002.00657.x","article-title":"Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients","volume":"62","author":"Vanrenterghem","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/ajkd.2002.33919","article-title":"Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients","volume":"40","author":"Nissenson","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib11","article-title":"Guideline on Comparability of Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance","year":"2003"},{"issue":"suppl 4","key":"10.1016\/j.semnephrol.2006.05.008_bib12","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1093\/ndt\/gfh1085","article-title":"Follow-on biologics: Challenges of the \u2018next generation.\u2019","volume":"20","author":"Schellekens","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib13","first-page":"436","article-title":"CERA (continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia","volume":"4","author":"Macdougall","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib14","first-page":"227A","article-title":"The discovery and characterization of CERA, an innovative agent for the treatment of anemia","volume":"100","author":"Haselbeck","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib15","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1200\/jco.2004.22.14_suppl.6692","article-title":"CERA (continuous erythropoiesis receptor activator): Dose-response, pharmacokinetics and tolerability in phase I multiple ascending dose studies","volume":"22","author":"Dougherty","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib16","first-page":"759A","article-title":"Pharmacologic profile of CERA (continuous erythropoietin receptor activator) in chronic kidney disease patients following intravenous and subcutaneous administration","volume":"16","author":"Macdougall","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib17","first-page":"27A","article-title":"Subcutaneous CERA (continuous erythropoiesis receptor activator) has potent erythropoietic activity in dialysis patients with chronic renal anemia: An exploratory multiple-dose study","volume":"14","author":"de Francisco","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib18","first-page":"544A","article-title":"CERA (continuous erythropoietin receptor activator) administered up to once every 3 weeks corrects anemia in patients with chronic kidney disease not on dialysis","volume":"15","author":"Provenzano","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib19","author":"Besarab","year":"2004","journal-title":"Intravenous CERA (continuous erythropoiesis receptor activator) administered once weekly or once every 2 weeks maintain haemoglobin levels in haemodialysis patients with chronic renal anaemia"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib20","first-page":"543A","article-title":"CERA (continuous erythropoietin receptor activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks","volume":"15","author":"Locatelli","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 15","key":"10.1016\/j.semnephrol.2006.05.008_bib21","first-page":"14S","article-title":"CERA (continuous erythropoietin receptor activator) in patients with multiple myeloma: An exploratory phase I-II dose escalation study","volume":"22","author":"Dmoszynska","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1126\/science.273.5274.458","article-title":"Small peptides as potent mimetics of the protein hormone erythropoietin","volume":"273","author":"Wrighton","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.2904.2904","article-title":"Preclinical evaluation of Hematide\u2122, a novel erythropoietic receptor agonist for the treatment of anemia caused by kidney disease","volume":"104","author":"Woodburn","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib24","unstructured":"Woodburn KW, Winslow S, Leuther KK, et al: Hematide\u2122, a peptidic erythropoiesis stimulating agent that corrects anemia induced by partial nephrectomy and erythropoietin-specific antibodies in rats. Abstract presented at European Haematology Association, Stockholm, June, 2005"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib25","doi-asserted-by":"crossref","unstructured":"Stead R, Lambert J, Wessels D, et al: Hematide\u2122, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates dose dependent activity in a phase 1 single dose, dose escalating study in normal healthy volunteers. Abstract presented at European Haematology Association, Stockholm, June, 2005","DOI":"10.1200\/jco.2005.23.16_suppl.8180"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib27","first-page":"546A","article-title":"Upregulation of endogenous EPO in healthy subjects by inhibition of HIF-PH","volume":"15","author":"Urquilla","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 5","key":"10.1016\/j.semnephrol.2006.05.008_bib28","first-page":"v195","article-title":"Pharmacological stabilization of HIF increases hemoglobin concentration in anemic patients with chronic kidney disease","volume":"20","author":"Wiecek","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib29","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1097\/01.ASN.0000092792.97122.E0","article-title":"HIF-1: An oxygen response system with special relevance to the kidney","volume":"14","author":"Maxwell","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib30","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1126\/science.1079085","article-title":"Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein","volume":"299","author":"Kochendoerfer","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib31","doi-asserted-by":"crossref","first-page":"24773","DOI":"10.1074\/jbc.274.35.24773","article-title":"An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties","volume":"274","author":"Sytkowski","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib32","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1073\/pnas.96.21.12156","article-title":"Mimicry of erythropoietin by a nonpeptide molecule","volume":"96","author":"Qureshi","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(95)90351-8","article-title":"Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals","volume":"80","author":"Klingmuller","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib34","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2004-06-2501","article-title":"Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/1043034041361172","article-title":"Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions","volume":"15","author":"Schwenter","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.semnephrol.2006.05.008_bib36","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2002-02-0605","article-title":"Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy","volume":"100","author":"Binley","year":"2002","journal-title":"Blood"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092950600074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027092950600074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T05:14:12Z","timestamp":1628140452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027092950600074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S027092950600074X"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2006.05.008","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}